Invion AI Stock Analysis
Invion (IVIXF) AI Stock Analysis
Invion
(Other OTC:IVIXF)
No summary available
Invion (IVIXF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.08M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- -3.38
- Revenue Growth
- ―
- EPS Growth
- 46.36%
- Country
- US
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being...
Invion Peers Comparison
Overall Rating
AU:MVP57Neutral
AU:PER45Neutral
AU:PKP39Underperform
AU:RGT37Underperform
AU:IDT34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | AUD 48.44M | 76.78 | 1.13% | ― | 8.99% | 450.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | AUD 6.94M | -0.73 | -65.33% | ― | ― | 72.60% | |
| 39Underperform | AUD 18.75M | -5.07 | 4388.00% | ― | -19.73% | 50.34% | |
| 37Underperform | AUD 2.48M | -0.20 | 102.60% | ― | 17.56% | 75.11% | |
| 34Underperform | AUD 14.06M | -5.31 | -13.81% | ― | 5.93% | 66.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IVIXF | Invion Ltd. | 0.04 | 0.00 | 0.00% | |
| AU:PER | Percheron Therapeutics Limited | ― | ― | ― | |
| AU:RGT | Argent Biopharma Ltd | 0.02 | -0.06 | -74.39% | |
| AU:MVP | Medical Developments International Limited | 0.43 | -0.13 | -23.21% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.01 | -30.00% | |
| AU:IDT | IDT Australia Limited | 0.03 | -0.02 | -41.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
